Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about N-acetyl cysteine improves efficacy of adoptive T cell immunotherapy for melanoma
A collaborative team of investigators at the Medical University of South Carolina (MUSC) and Loyola University have demonstrated for the first time that culturing T cells in N-acetyl cysteine (NAC) before they are infused as immunotherapy improves effectiveness and outcomes in a preclinical model of melanoma.
- Read more about US FDA accepts sNDA for Allergan's Avycaz
The US Food and Drug Administration (FDA) has accepted for filing Allergan's supplemental New Drug Application (sNDA) for Avycaz (ceftazidime and avibactam), seeking the addition of new phase 3 clinical trial data evaluating Avycaz in patients with complicated urinary tract infections (cUTI), including pyelonephritis, due to designated susceptible pathogens to the current product label.
- Read more about SkylineDx get Japanese patent for prognostic SKY92 gene signature
SkylineDx,a commercial-stage biotech company, has received a notice of allowance for a Japanese patent related to its prognostic SKY92 gene signature for multiple myeloma. The announcement comes as SkylineDx prepares to attend the 78th Annual Meeting of the Japanese Society of Hematology (JSH2016) in Pacifico Yokohama, October 13 -15, 2016.
- Read more about FDA Grants QIDP and Fast Track Designations to VT-1161
Viamet Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations to VT-1161, a novel oral agent for the treatment of recurrent vulvovaginal candidiasis (RVVC), or recurrent vaginal yeast infection, a common and difficult to treat condition in women. There are no approved therapies in the United States for RVVC.
- Read more about Daiichi Sankyo declare First Patient Enrolled in Phase 3 QuANTUM-First Trial
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been enrolled in the global phase 3 QuANTUM-First study evaluating the oral FLT3-ITD inhibitor quizartinib in patients with newly-diagnosed FLT3-ITD-positive (+) acute myeloid leukemia (AML).
- Read more about Alzheimer’s disease could be treated with gene therapy, suggests animal study
Researchers have prevented the development of Alzheimer’s disease in mice by using a virus to deliver a specific gene into the brain. The early-stage findings, by scientists from Imperial College London, open avenues for potential new treatments for the disease.
- Read more about Triple-drug chemotherapy with topotecan helps preserve vision in retinoblastoma patients
St. Jude Children’s Research Hospital researchers report a topotecan-based chemotherapy regimen should be considered front-line therapy for patients with advanced bilateral retinoblastoma; an eye cancer in young children.
- Read more about US FDA approved LBT's Automated Plate Assessment System (APAS®)
Clever Culture Systems AG (CCS), the Swiss based joint venture between Australian medical technology company LBT Innovations Limited (ASX: LBT) and Hettich AG (Switzerland) has received clearance of its 510(k) de novo submission to the US Food and Drug Administration (FDA) for APAS® as a Class II medical device.
- Read more about Novartis' Tafinlar + Mekinist show superior overall survival benefit in phase III COMBI-v study
Novartis announced data from the phase III COMBI-v study demonstrating an overall survival (OS) and a progression-free survival benefit for patients with BRAF V600 mutation-positive advanced melanoma when treated first-line with the combination of Tafinlar (dabrafenib) + Mekinist (trametinib) compared to vemurafenib monotherapy. The results of this study, which was conducted in 704 patients, are being presented at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen.

[adsense:336x280:8701650588]
- Read more about Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival in Phase II study
Novartis announced updated results from a Phase II study (ASCEND-3), which demonstrated that anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients taking Zykadia® (ceritinib) as their first ALK inhibitor (post-chemotherapy) had a median progression-free survival (PFS) of 18.4 months [95% CI: 10.9-26.3; median follow-up time of 25.9 months, as measured by blinded independent review committee (BIRC).Results were presented during an oral session at the Annual European Society for Medical Oncology Congress (ESMO) in Copenhagen.